Skip to content
OpenCapital
Get started

Metagenomi Therapeutics, Inc. MGX Q1 2026 earnings

Reported May 11, 2026 · Before market open

Revenue$1.2MMiss by $4.7M
EPS-$0.61Miss by $0.01
Revenue estimate$5.9M
EPS estimate-$0.60

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$3.0M
EPS estimate-$0.55

Versus estimates

Revenue

Q1 2026$1.2MMiss by $4.7M
Q4 2025$3.9MMiss by $3.4MQ3 2025$8.7MBeat by $836.4KQ2 2025$8.5MBeat by $573.0KQ1 2025$4.1MMiss by $4.2MQ4 2024$9.6MBeat by $382.7K

Diluted EPS

Q1 2026-$0.61Miss by $0.01
Q4 2025-$0.60Miss by $0.02Q3 2025-$0.55Beat by $0.05Q2 2025-$0.54Beat by $0.14Q1 2025-$0.68Miss by $0.06Q4 2024-$0.63Miss by $0.01

Ask the moment Metagenomi Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Metagenomi Therapeutics, Inc. report Q1 2026 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q1 2026 earnings on May 11, 2026 before market open.
What were Metagenomi Therapeutics, Inc. 's Q1 2026 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of $1.2M and eps of $-0.61 for Q1 2026.
Did Metagenomi Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $5.9M by $4.7M. EPS missed the consensus estimate of $-0.60 by $0.01.
How did Metagenomi Therapeutics, Inc. 's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 69.8% from $4.1M a year earlier and eps grew 10.3% from $-0.68.
Where can I find Metagenomi Therapeutics, Inc. 's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-216763) and the 10-Q periodic report (0001193125-26-216774) directly on SEC EDGAR. The filing index links above go to sec.gov.